Clinical experiment designed to assess clinical efficacy targeting SIRT in human. Primary outcome: Validate Sirtuin Dysfunction Validation in Parkinson's Disease
Description
Sirtuin Dysfunction Validation in Parkinson's Disease
Background and Rationale
Parkinson's disease (PD) is characterized by progressive neurodegeneration with accumulating evidence implicating mitochondrial dysfunction and impaired protein quality control. The Sirtuin Dysfunction Hypothesis proposes that dysregulation of NAD+-dependent sirtuin deacetylases contributes to PD pathogenesis through compromised mitochondrial biogenesis, defective autophagy, and increased oxidative stress. This comprehensive clinical study aims to validate sirtuin dysfunction in PD patients through multi-modal assessment of SIRT1, SIRT2, and SIRT3 activities, coupled with a randomized controlled trial of SIRT1 activator intervention. The study employs a two-phase design: Phase 1 involves cross-sectional comparison of PD patients (n=120) versus age-matched controls (n=80) to quantify sirtuin enzyme activities, NAD+/NADH ratios, mitochondrial respiratory capacity, and autophagy markers in peripheral blood mononuclear cells and plasma....
Sirtuin Dysfunction Validation in Parkinson's Disease
Background and Rationale
Parkinson's disease (PD) is characterized by progressive neurodegeneration with accumulating evidence implicating mitochondrial dysfunction and impaired protein quality control. The Sirtuin Dysfunction Hypothesis proposes that dysregulation of NAD+-dependent sirtuin deacetylases contributes to PD pathogenesis through compromised mitochondrial biogenesis, defective autophagy, and increased oxidative stress. This comprehensive clinical study aims to validate sirtuin dysfunction in PD patients through multi-modal assessment of SIRT1, SIRT2, and SIRT3 activities, coupled with a randomized controlled trial of SIRT1 activator intervention. The study employs a two-phase design: Phase 1 involves cross-sectional comparison of PD patients (n=120) versus age-matched controls (n=80) to quantify sirtuin enzyme activities, NAD+/NADH ratios, mitochondrial respiratory capacity, and autophagy markers in peripheral blood mononuclear cells and plasma. Phase 2 consists of a 24-week randomized, double-blind, placebo-controlled trial testing resveratrol (a SIRT1 activator) in PD patients, measuring motor function via UPDRS-III, cognitive performance, and biomarker changes. Key innovations include comprehensive sirtuin profiling in living PD patients, correlation with clinical severity, and therapeutic intervention targeting this pathway. Primary endpoints encompass sirtuin enzymatic activities, NAD+ metabolomics, and clinical response to SIRT1 activation. This study addresses a critical gap in understanding metabolic dysfunction in neurodegeneration and may identify novel therapeutic targets for disease modification in Parkinson's disease.
This experiment directly tests predictions arising from the following hypotheses:
Phase 1 (Months 1-12): Recruit 120 PD patients (Hoehn-Yahr stages I-III) and 80 age-matched controls. Collect fasting blood samples at baseline and 6 months. Isolate PBMCs using Ficoll gradient centrifugation. Measure SIRT1, SIRT2, SIRT3 activities using fluorometric deacetylase assays. Quantify NAD+/NADH ratios via enzymatic cycling assays. Assess mitochondrial function using Seahorse XF analyzer measuring oxygen consumption rates. Evaluate autophagy markers (LC3-II/I ratio, p62 levels) by Western blot. Perform plasma metabolomics focusing on NAD+ biosynthesis pathway. Clinical assessments include UPDRS-III, MoCA, and PDQ-39 quality of life scores. Phase 2 (Months 13-24): Randomize 80 PD patients to resveratrol (1000mg daily) or placebo for 24 weeks. Primary endpoint: change in UPDRS-III motor scores. Secondary endpoints include cognitive testing, biomarker changes, and safety monitoring. Blood sampling at weeks 0, 4, 12, and 24 for sirtuin activities and NAD+ levels. Statistical analysis using mixed-effects models adjusting for age, disease duration, and baseline severity. Sample size calculations based on 80% power to detect 20% difference in sirtuin activities between groups (α=0.05). Monitor adverse events and medication compliance throughout study duration.
Expected Outcomes
1. PD patients will show 30-50% reduced SIRT1 and SIRT3 activities compared to controls (p<0.01), with stronger correlations observed in advanced disease stages (Hoehn-Yahr III vs I).
2. NAD+/NADH ratios will be significantly decreased in PD patients by 25-40% (p<0.001), correlating inversely with UPDRS-III motor severity scores (r=-0.6, p<0.001).
3. Mitochondrial oxygen consumption rates will be reduced by 20-35% in PD patient PBMCs compared to controls (p<0.01), with impaired coupling efficiency.
4. Autophagy dysfunction will be evident through decreased LC3-II/I ratios (40% reduction, p<0.01) and accumulated p62 levels (2-fold increase, p<0.001) in PD patients.
5. Resveratrol treatment will improve UPDRS-III scores by 15-20% compared to placebo (p<0.05) and restore sirtuin activities toward control levels.
6. Plasma metabolomics will reveal disrupted NAD+ biosynthesis pathway with reduced nicotinamide and increased quinolinic acid levels in PD patients (fold-change >1.5, FDR<0.05).
Success Criteria
• Demonstrate statistically significant reduction in at least 2 of 3 sirtuin enzymes (SIRT1, SIRT2, SIRT3) in PD patients vs controls with effect size >0.5
• Establish significant correlation between sirtuin dysfunction and clinical severity (UPDRS-III) with correlation coefficient r>0.4, p<0.01
• Show meaningful clinical improvement in resveratrol group: ≥3-point reduction in UPDRS-III scores compared to placebo (clinically meaningful difference)
• Demonstrate target engagement: ≥20% increase in SIRT1 activity in resveratrol-treated patients compared to baseline
• Achieve recruitment and retention targets: >90% enrollment completion and <15% dropout rate across both study phases
• Identify robust biomarker signature: NAD+/NADH ratio changes correlating with clinical measures and showing >70% sensitivity/specificity for PD classification
TARGET GENE
SIRT
MODEL SYSTEM
human
ESTIMATED COST
$6,550,000
TIMELINE
49 months
PATHWAY
N/A
SOURCE
wiki
PRIMARY OUTCOME
Validate Sirtuin Dysfunction Validation in Parkinson's Disease
Phase 1 (Months 1-12): Recruit 120 PD patients (Hoehn-Yahr stages I-III) and 80 age-matched controls. Collect fasting blood samples at baseline and 6 months. Isolate PBMCs using Ficoll gradient centrifugation. Measure SIRT1, SIRT2, SIRT3 activities using fluorometric deacetylase assays. Quantify NAD+/NADH ratios via enzymatic cycling assays. Assess mitochondrial function using Seahorse XF analyzer measuring oxygen consumption rates. Evaluate autophagy markers (LC3-II/I ratio, p62 levels) by Western blot. Perform plasma metabolomics focusing on NAD+ biosynthesis pathway. Clinical assessments include UPDRS-III, MoCA, and PDQ-39 quality of life scores. Phase 2 (Months 13-24): Randomize 80 PD patients to resveratrol (1000mg daily) or placebo for 24 weeks.
...
Phase 1 (Months 1-12): Recruit 120 PD patients (Hoehn-Yahr stages I-III) and 80 age-matched controls. Collect fasting blood samples at baseline and 6 months. Isolate PBMCs using Ficoll gradient centrifugation. Measure SIRT1, SIRT2, SIRT3 activities using fluorometric deacetylase assays. Quantify NAD+/NADH ratios via enzymatic cycling assays. Assess mitochondrial function using Seahorse XF analyzer measuring oxygen consumption rates. Evaluate autophagy markers (LC3-II/I ratio, p62 levels) by Western blot. Perform plasma metabolomics focusing on NAD+ biosynthesis pathway. Clinical assessments include UPDRS-III, MoCA, and PDQ-39 quality of life scores. Phase 2 (Months 13-24): Randomize 80 PD patients to resveratrol (1000mg daily) or placebo for 24 weeks. Primary endpoint: change in UPDRS-III motor scores. Secondary endpoints include cognitive testing, biomarker changes, and safety monitoring. Blood sampling at weeks 0, 4, 12, and 24 for sirtuin activities and NAD+ levels. Statistical analysis using mixed-effects models adjusting for age, disease duration, and baseline severity. Sample size calculations based on 80% power to detect 20% difference in sirtuin activities between groups (α=0.05). Monitor adverse events and medication compliance throughout study duration.
Expected Outcomes
1. PD patients will show 30-50% reduced SIRT1 and SIRT3 activities compared to controls (p<0.01), with stronger correlations observed in advanced disease stages (Hoehn-Yahr III vs I).
2. NAD+/NADH ratios will be significantly decreased in PD patients by 25-40% (p<0.001), correlating inversely with UPDRS-III motor severity scores (r=-0.6, p<0.001).
3. Mitochondrial oxygen consumption rates will be reduced by 20-35% in PD patient PBMCs compared to controls (p<0.01), with impaired coupling efficiency.
4.
...
1. PD patients will show 30-50% reduced SIRT1 and SIRT3 activities compared to controls (p<0.01), with stronger correlations observed in advanced disease stages (Hoehn-Yahr III vs I).
2. NAD+/NADH ratios will be significantly decreased in PD patients by 25-40% (p<0.001), correlating inversely with UPDRS-III motor severity scores (r=-0.6, p<0.001).
3. Mitochondrial oxygen consumption rates will be reduced by 20-35% in PD patient PBMCs compared to controls (p<0.01), with impaired coupling efficiency.
4. Autophagy dysfunction will be evident through decreased LC3-II/I ratios (40% reduction, p<0.01) and accumulated p62 levels (2-fold increase, p<0.001) in PD patients.
5. Resveratrol treatment will improve UPDRS-III scores by 15-20% compared to placebo (p<0.05) and restore sirtuin activities toward control levels.
6. Plasma metabolomics will reveal disrupted NAD+ biosynthesis pathway with reduced nicotinamide and increased quinolinic acid levels in PD patients (fold-change >1.5, FDR<0.05).
Success Criteria
• Demonstrate statistically significant reduction in at least 2 of 3 sirtuin enzymes (SIRT1, SIRT2, SIRT3) in PD patients vs controls with effect size >0.5
• Establish significant correlation between sirtuin dysfunction and clinical severity (UPDRS-III) with correlation coefficient r>0.4, p<0.01
• Show meaningful clinical improvement in resveratrol group: ≥3-point reduction in UPDRS-III scores compared to placebo (clinically meaningful difference)
• Demonstrate target engagement: ≥20% increase in SIRT1 activity in resveratrol-treated patients compared to baseline
• Achieve recruitment
...
• Demonstrate statistically significant reduction in at least 2 of 3 sirtuin enzymes (SIRT1, SIRT2, SIRT3) in PD patients vs controls with effect size >0.5
• Establish significant correlation between sirtuin dysfunction and clinical severity (UPDRS-III) with correlation coefficient r>0.4, p<0.01
• Show meaningful clinical improvement in resveratrol group: ≥3-point reduction in UPDRS-III scores compared to placebo (clinically meaningful difference)
• Demonstrate target engagement: ≥20% increase in SIRT1 activity in resveratrol-treated patients compared to baseline
• Achieve recruitment and retention targets: >90% enrollment completion and <15% dropout rate across both study phases
• Identify robust biomarker signature: NAD+/NADH ratio changes correlating with clinical measures and showing >70% sensitivity/specificity for PD classification